Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) CFO Erick Lucera sold 1,991 shares of the stock in a transaction dated Friday, November 13th. The shares were sold at an average price of $16.82, for a total transaction of $33,488.62. Following the completion of the transaction, the chief financial officer directly owned 117,775 shares of the company’s stock, valued at approximately $1,980,975.50. The trade was a 1.66% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Dyne Therapeutics Trading Down 2.7%
DYN traded down $0.46 on Monday, hitting $16.70. The company had a trading volume of 1,849,634 shares, compared to its average volume of 2,331,563. The business’s fifty day simple moving average is $16.96 and its 200 day simple moving average is $19.33. The company has a quick ratio of 12.99, a current ratio of 12.99 and a debt-to-equity ratio of 0.21. Dyne Therapeutics, Inc. has a 12-month low of $14.00 and a 12-month high of $27.31. The company has a market cap of $3.13 billion, a PE ratio of -4.60 and a beta of 1.22.
Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.15). During the same quarter last year, the firm posted ($0.76) earnings per share. Equities research analysts expect that Dyne Therapeutics, Inc. will post -3.81 EPS for the current year.
Hedge Funds Weigh In On Dyne Therapeutics
A number of large investors have recently bought and sold shares of DYN. Cetera Investment Advisers bought a new stake in shares of Dyne Therapeutics during the third quarter worth $262,000. Jump Financial LLC bought a new position in shares of Dyne Therapeutics in the third quarter worth about $5,458,000. Steward Partners Investment Advisory LLC increased its stake in Dyne Therapeutics by 10.5% in the 3rd quarter. Steward Partners Investment Advisory LLC now owns 7,676 shares of the company’s stock worth $124,000 after buying an additional 732 shares during the period. Aegis Wealth Management LLC increased its stake in Dyne Therapeutics by 6.7% in the 3rd quarter. Aegis Wealth Management LLC now owns 160,030 shares of the company’s stock worth $2,578,000 after buying an additional 10,000 shares during the period. Finally, Cibc World Market Inc. increased its stake in Dyne Therapeutics by 13.8% in the 3rd quarter. Cibc World Market Inc. now owns 86,243 shares of the company’s stock worth $1,389,000 after buying an additional 10,460 shares during the period. Hedge funds and other institutional investors own 96.68% of the company’s stock.
Analyst Upgrades and Downgrades
Several analysts recently weighed in on DYN shares. Wall Street Zen lowered Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. Jefferies Financial Group reiterated a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research report on Wednesday, September 30th. Cantor Fitzgerald reissued a “buy” rating on shares of Dyne Therapeutics in a research note on Wednesday, September 30th. Morgan Stanley reduced their target price on shares of Dyne Therapeutics from $45.00 to $36.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 9th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $38.00 price target on shares of Dyne Therapeutics in a research note on Wednesday, September 30th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $31.29.
About Dyne Therapeutics
Dyne Therapeutics is a clinical-stage biotechnology company developing therapies for genetically driven muscle diseases. Its research uses the FORCE platform, which is designed to deliver oligonucleotide medicines to muscle tissue. The company’s programs include DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy in patients whose genetic mutations are amenable to exon 51 skipping. Dyne has also pursued a program for facioscapulohumeral muscular dystrophy. Its therapies remain in development, and the company does not have an approved product.
Further Reading
- Five stocks we like better than Dyne Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
